Philip Janiak, Corteria Pharmaceuticals CEO
September 7, 2023 03:00 AM EDT
Financing

French biotech Cor­te­ria se­cures $70M to re­vive ex-Sanofi heart drugs 

Nicole DeFeudis

Editor

In­vestors are pump­ing $70 mil­lion in­to a Paris-based biotech’s at­tempt to re­vive two of Sanofi’s for­mer car­dio­vas­cu­lar pro­grams.

Cor­te­ria Phar­ma­ceu­ti­cals, found­ed in 2021, on Thurs­day un­veiled a €65 mil­lion ($70.7 mil­lion) Se­ries A round co-led by Or­biMed and Jeito Cap­i­tal that aims to ad­vance a se­ries of heart drugs in­to the clin­ic. Founders Philip Ja­ni­ak and Marie-Lau­re Ozoux hail from Sanofi, which an­nounced in 2019 that it was drop­ping car­dio and di­a­betes re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk looks be­yond weight loss and di­a­betes to ex­pand in new ill­ness­es

As­traZeneca counts on ‘dif­fi­cult-to-copy’ ther­a­pies for big 2030 goal and be­yond

With $5B in Chi­na sales, As­traZeneca dou­bles down on Chi­nese bio­phar­ma in­no­va­tion

‘A new era of growth’: As­traZeneca aims for $80B rev­enue, 20 new drugs by 2030

AI biotech Ex­sci­en­tia to trim near­ly a quar­ter of work­force, fol­low­ing pipeline cut and CEO fir­ing

sponsored

Back to the fu­ture: From tar­get-se­lec­tive drug de­sign to AI-en­abled polyphar­ma­col­o­gy

A service from the Financial Times